Diagnos Laboratorium Utama PT Tbk (JK:DGNS) — Market Cap & Net Worth
Market Cap & Net Worth: Diagnos Laboratorium Utama PT Tbk (DGNS)
Diagnos Laboratorium Utama PT Tbk (JK:DGNS) has a market capitalization of $20.36 Million (Rp347.50 Billion) as of September 18, 2026. Listed on the JK stock exchange, this Indonesia-based company holds position #25143 globally and #547 in its home market, demonstrating a -0.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diagnos Laboratorium Utama PT Tbk's stock price Rp278.00 by its total outstanding shares 1250000000 (1.25 Billion). Also see Diagnos Laboratorium Utama PT Tbk balance sheet assets for a full breakdown of the balance sheet.
Diagnos Laboratorium Utama PT Tbk Market Cap History: 2021 to 2026
Diagnos Laboratorium Utama PT Tbk's market capitalization history from 2021 to 2026. Data shows growth from $54.57 Million to $20.36 Million (0.59% CAGR). Also see DGNS cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Diagnos Laboratorium Utama PT Tbk is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Jakarta Stock Exchange Composite Index
JKSE
|
$507.18 Billion | 0.00% | #535 of 864 |
Weight: Diagnos Laboratorium Utama PT Tbk's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Diagnos Laboratorium Utama PT Tbk Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diagnos Laboratorium Utama PT Tbk's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Diagnos Laboratorium Utama PT Tbk for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Diagnos Laboratorium Utama PT Tbk's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Diagnos Laboratorium Utama PT Tbk's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $54.57 Million | $302.18 Billion | $64.30 Billion | 0.00x | 0.00x |
| 2022 | $17.87 Million | $192.89 Billion | $12.66 Billion | 0.00x | 0.00x |
| 2023 | $18.02 Million | $145.70 Billion | -$13.66 Billion | 0.00x | N/A |
| 2024 | $14.28 Million | $163.07 Billion | $747.44 Million | 0.00x | 0.02x |
Competitor Companies of DGNS by Market Capitalization
Companies near Diagnos Laboratorium Utama PT Tbk in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Diagnos Laboratorium Utama PT Tbk to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Diagnos Laboratorium Utama PT Tbk by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #160 globally with a market cap of $150.10 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #470 globally with a market cap of $58.08 Billion USD ( CN¥396.94 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #577 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $658.32 |
| #160 | Danaher Corporation | NYSE:DHR | $150.10 Billion | $212.50 |
| #470 | WuXi AppTec Co Ltd | SHG:603259 | $58.08 Billion | CN¥160.49 |
| #577 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $366.31 |
Diagnos Laboratorium Utama PT Tbk Historical Marketcap From 2021 to 2026
Between 2021 and today, Diagnos Laboratorium Utama PT Tbk's market cap moved from $54.57 Million to $ 20.36 Million, with a yearly change of 0.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rp20.36 Million | +51.09% |
| 2025 | Rp13.48 Million | -5.64% |
| 2024 | Rp14.28 Million | -20.73% |
| 2023 | Rp18.02 Million | +0.82% |
| 2022 | Rp17.87 Million | -67.25% |
| 2021 | Rp54.57 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Diagnos Laboratorium Utama PT Tbk was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.36 Million USD |
| MoneyControl | $20.36 Million USD |
| MarketWatch | $20.36 Million USD |
| marketcap.company | $20.36 Million USD |
| Reuters | $20.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Diagnos Laboratorium Utama PT Tbk
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want t… Read more